Compare TransMedics Group Inc (TMDX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Xcel Energy Inc — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Xcel Energy Inc trades at $73.99 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 16.7× TransMedics Group Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Xcel Energy Inc for 61 Days on average.
| TMDX | XEL | |
|---|---|---|
Market Cap | $2.74B | $45.82B |
Volume | 949,331 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $150.42 | $83.91 |
52-Week Low | $61.99 | $69.39 |
Typical Hold Time | 24 Days | 61 Days |
Enterprise Value | $3.13B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Xcel Energy (XEL) trades at $73.78, up 1.87% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growing data center power demand and a $60B capital investment plan driving future growth. Analyst consensus remains positive with a $90.83 price target representing 23% upside potential.
XEL offers attractive total return potential through earnings growth and dividend yield, supported by regulated utility business model and infrastructure investments. Key risks include wildfire liabilities, rising interest rates impacting financing costs, and execution challenges with large capital projects. The stock presents a balanced opportunity for income and growth investors seeking utility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
